Crawford S, Smith RA, Kuwabara SA, et al. Risks factors and treatment use related to infertility and impaired fecundity among reproductive-aged women. J Womens Health (Larchmt). 2017;26:500-510. Abstract
Infertility. Centers for Disease Control and Prevention website. https://www.cdc.gov/nchs/fastats/infertility.htm. Updated July 15, 2016. Accessed December 1, 2017.
Smith S, Pfeifer SM, Collins JA. Diagnosis and management of female infertility. JAMA. 2003;290:1767-1770. Abstract
Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015;103:e44-e50. Abstract
Practice Committee of the American Society for Reproductive Medicine. Role of tubal surgery in the era of assisted reproductive technology: a committee opinion. Fertil Steril. 2015;103:e37-e43. Abstract
Macer ML, Taylor HS. Endometriosis and infertility: a review of the pathogenesis and treatment of endometriosis-associated infertility. Obstet Gynecol Clin North Am. 2012;39:535-549. Abstract
Birth expectations of U.S. women aged 15-44. Centers for Disease Control and Prevention website. https://www.cdc.gov/nchs/products/databriefs/db260.htm. Updated October 13, 2016. Accessed December 1, 2017.
Levine H, Jørgensen N, Martino-Andrade A, et al. Temporal trends in sperm count: a systematic review and meta-regression analysis. Hum Reprod Update.2017;23:646-659. Abstract
Argyle CE, Harper JC, Davies MC. Oocyte cryopreservation: where are we now? Hum Reprod Update. 2016;22:440-449. Abstract
Mills M, Rindfuss RR, McDonald P, et al. Why do people postpone parenthood? Reasons and social policy incentives. Hum Reprod Update. 2011;17:848-860. Abstract
Daniluk JC, Koert E. Childless women's beliefs and knowledge about oocyte freezing for social and medical reasons. Hum Reprod. 2016;31:2313-2320. Abstract
Meissner C, Shippert C, von Versen-Höynck F, et al. Awareness, knowledge, and perceptions of infertility, fertility assessment, and assisted reproductive technologies in the era of oocyte freezing among female and male university students. J Assist Reprod Genet. 2016;33:719-729. Abstract
Milman LW, Senapati S, Sammel MD, et al. Assessing reproductive choices of women and the likelihood of oocyte cryopreservation in the era of elective oocyte freezing. Fertil Steril. 2017;107:1214-1222.e3.
Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2015;103:e9-e17. Abstract
Practice Committee of the American Society for Reproductive Medicine. Diagnostic evaluation of the infertile female: a committee opinion. Fertil Steril. 2015;103:e44-e50. Abstract
Leader B, Baker VL. Maximizing the clinical utility of antimüllerian hormone testing in women's health. Curr Opin Obstet Gynecol. 2014;26:226-236. Abstract
Seifer DB, Baker VL, Leader B. Age-specific serum anti-Müllerian hormone values for 17,120 women presenting to fertility centers within the United States. Fertil Steril. 2011;95:747-750. Abstract
Tal R, Seifer DB. Ovarian reserve testing: a user's guide. Am J Obstet Gynecol. 2017;217:129-140. Abstract
La Marca A, Sighinolfi G, Radi D, et al. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16:113-130. Abstract
Broer SL, van Disseldorp J, Broeze KA, et al. Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: an individual patient data approach. Hum Reprod Update. 2013;19;26-36. Abstract
Kallio S, Puurunen J, Ruokonen A, et al. Antimüllerian hormone levels decrease in women using combined contraception independently of administration route. Fertil Steril. 2013;99:1305-1310. Abstract
Steiner AZ, Pritchard D, Stanczyk FZ, et al. Association between biomarkers of ovarian reserve and infertility among older women of reproductive age. JAMA. 2017;318:1367-1376. Abstract
Santoro N. Using antimüllerian hormone to predict fertility. JAMA. 2017;318:1333-1334. Abstract

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Moderator

Benjamin Leader, MD, PhD

Director, Clinical Research, ReproSource, Inc., Woburn, Massachusetts

Disclosures

Disclosure: Benjamin Leader, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Siemens Healthcare Diagnostics Inc.
Owns stock, stock options, or bonds from: ReproSource, Inc. Other: Employed by a commercial interest: ReproSource, Inc.

Dr Leader does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Leader does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Valerie Baker, MD

Professor, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Sunnyvale, California

Disclosures

Disclosure: Valerie Baker, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Siemens Healthcare Diagnostics Inc.
Received grants for clinical research from: Beckman Coulter, Inc.; Roche

Dr Baker does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Baker does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Carol Lesser, MSN, NP

Nurse Practitioner, Boston IVF, Waltham, Massachusetts

Disclosures

Disclosure: Carol Lesser, MSN, NP, has disclosed no relevant financial relationships.

Ms Lesser does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Lesser does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

William Schoolcraft, MD, HCLD

Founder and Medical Director, Colorado Center for Reproductive Medicine, Lone Tree, Colorado

Disclosures

Disclosure: William Schoolcraft, MD, HCLD, has disclosed no relevant financial relationships.

Dr Schoolcraft does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Schoolcraft does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Stacey J.P. Ullman, MHS

Senior Scientific Director, Medscape, LLC

Disclosures

Disclosure: Stacey J.P. Ullman, MHS, has disclosed no relevant financial relationships.

Christina T. Loguidice, MS

Medical Writer, Burlington, NJ

Disclosures

Disclosure: Christina T. Loguidice, MS, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

CME / CE

Evaluation of Fertility: A Cornerstone to Improved Reproductive Health for Women

Authors: Benjamin Leader, MD, PhD; Valerie Baker, MD; Carol Lesser, MSN, NP; William Schoolcraft, MD, HCLD
CME / CE Released: 12/18/2017
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 12/18/2019, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for obstetricians/gynecologists, in vitro fertilization specialists, primary care physicians, reproductive endocrinologists, nurses, pharmacists, and others involved in female fertility care.

The goal of this activity is to discuss the options for ovarian reserve testing for patients with infertility as well as women interested in fertility preservation and future family building.

Upon completion of this activity, participants will:

Have increased knowledge regarding
- The prevalence of fertility issues among women of different ages
- The collaborative role of the healthcare team in managing the patient with infertility or seeking fertility preservation
Have greater competence related to
- The use of anti-Müllerian hormone assessment to evaluate ovarian reserve

Disclosures

Moderator

Benjamin Leader, MD, PhD

Director, Clinical Research, ReproSource, Inc., Woburn, Massachusetts

Disclosures

Disclosure: Benjamin Leader, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Siemens Healthcare Diagnostics Inc.
Owns stock, stock options, or bonds from: ReproSource, Inc. Other: Employed by a commercial interest: ReproSource, Inc.

Dr Leader does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Leader does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

Valerie Baker, MD

Professor, Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Sunnyvale, California

Disclosures

Disclosure: Valerie Baker, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Siemens Healthcare Diagnostics Inc.
Received grants for clinical research from: Beckman Coulter, Inc.; Roche

Dr Baker does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Baker does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Carol Lesser, MSN, NP

Nurse Practitioner, Boston IVF, Waltham, Massachusetts

Disclosures

Disclosure: Carol Lesser, MSN, NP, has disclosed no relevant financial relationships.

Ms Lesser does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Ms Lesser does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

William Schoolcraft, MD, HCLD

Founder and Medical Director, Colorado Center for Reproductive Medicine, Lone Tree, Colorado

Disclosures

Disclosure: William Schoolcraft, MD, HCLD, has disclosed no relevant financial relationships.

Dr Schoolcraft does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Schoolcraft does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Stacey J.P. Ullman, MHS

Senior Scientific Director, Medscape, LLC

Disclosures

Disclosure: Stacey J.P. Ullman, MHS, has disclosed no relevant financial relationships.

Christina T. Loguidice, MS

Medical Writer, Burlington, NJ

Disclosures

Disclosure: Christina T. Loguidice, MS, has disclosed no relevant financial relationships.

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For Nurses

Awarded 0.5 contact hour(s) of continuing nursing education for RNs and APNs; none of these credits is in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) (Universal Activity Number: 0461-0000-17-203-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Ob/Gyn & Women's Health

CME / CE

Evaluation of Fertility: A Cornerstone to Improved Reproductive Health for Women

Authors: Benjamin Leader, MD, PhD; Valerie Baker, MD; Carol Lesser, MSN, NP; William Schoolcraft, MD, HCLDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME / CE Released: 12/18/2017

Valid for credit through: 12/18/2019, 11:59 PM EST

processing....

None
中文

Educational Impact Challenge

The goal of this activity is to discuss the options for ovarian reserve testing for those patients interested in fertility preservation and future family building.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 4

CME / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

References

Faculty and Disclosures

Moderator

Benjamin Leader, MD, PhD

Panelists

Valerie Baker, MD

Carol Lesser, MSN, NP

William Schoolcraft, MD, HCLD

Editors

Stacey J.P. Ullman, MHS

Christina T. Loguidice, MS

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

CME / CE

Evaluation of Fertility: A Cornerstone to Improved Reproductive Health for Women

Target Audience and Goal Statement

Disclosures

Moderator

Benjamin Leader, MD, PhD

Panelists

Valerie Baker, MD

Carol Lesser, MSN, NP

William Schoolcraft, MD, HCLD

Editors

Stacey J.P. Ullman, MHS

Christina T. Loguidice, MS

CME Reviewer/Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Evaluation of Fertility: A Cornerstone to Improved Reproductive Health for Women

Educational Impact Challenge